Overview

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402)

Status:
Terminated
Trial end date:
2021-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare plasma and urine pharmacokinetic (PK)parameters of MK-3402 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3402 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerability of MK-3402 in participants with impaired renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.